ONCS
OncoSec Medical IncorporatedNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 8, 9:45 AM
    • Thinly traded nano cap OncoSec Medical (ONCS +6.9%) jumps out of the blocks this morning on increased volume in response to its announcement of positive interim results in a mid-stage study assessing ImmunoPulse IL-12 and Merck's (MRK -0.5%) KEYTRUDA (pembrolizumab) in patients with unresectable metastatic melanoma. The data will be presented on November 11 at the Society for Immunotherapy of Cancer Annual Meeting in National Harbor, MD.
    • In 15 patients determined to be unlikely to respond to a PD-1 inhibitor alone, 40% (n=6/15) responded to treatment with ImmunoPulse Il-12 and KEYTRUDA. The group included four complete responders and two partial responders.
    • ImmunoPulse IL-12 delivers a pulsed electric field to cells via a hand-held applicator which temporarily increases the porosity of the cell membranes (electroporation). DNA IL-12 is then delivered to the electroporated cells which triggers each cell to produce and secrete IL-12 protein which then identifies and eliminates cancer cells as part of a natural immune response.
    • Pembrolizumab helps the immune system fight tumor cells by blocking the interaction between PD-1, a cell surface receptor expressed on T cells and pro-B cells, and its ligands PD-L1 and PD-L2. PD-1 is an immune checkpoint which down regulates the immune system. Blocking its action activates the immune system to attack cancer cells.
    | Tue, Nov. 8, 9:45 AM | 29 Comments
  • Thu, Oct. 13, 4:02 PM
    • OncoSec Medical (NASDAQ:ONCS): FQ4 EPS of -$0.39 misses by $0.04.
    • Cash and equivalents of $28.7M
    • Press Release
    | Thu, Oct. 13, 4:02 PM
  • Fri, Jul. 22, 8:31 AM
    • OncoSec Medical (NASDAQ:ONCS) initiated with Buy rating and $6 (253% upside) price target by Rodman & Renshaw.
    • Invivo Therapeutics Holdings (NASDAQ:NVIV) initiated with Buy rating and $23.25 (254% upside) price target by Ladenburg Thalmann.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $105 (14% upside) price target by Baird.
    • Selecta Biosciences (Pending:SELB) initiated with Buy rating and $23 (64% upside) price target by Stifel Nicolaus.
    • Syros Pharmaceuticals (NASDAQ:SYRS) initiated with Neutral rating and $10 (11% downside risk) price target by H.C. Wainwright.
    • Voyager Therapeutics (NASDAQ:VYGR) initiated with Buy rating and $33 (161% upside) price target by Stifel Nicolaus.
    • AveXis (NASDAQ:AVXS) initiated with Market Perform rating by Wells Fargo.
    • Celgene (NASDAQ:CELG) initiated with Buy rating and $150 (40% upside) price target by Stifel Nicolaus.
    • ReWalk Robotics (NASDAQ:RWLK) initiated Overweight rating and $10 (49% upside) price target by Piper Jaffray.
    | Fri, Jul. 22, 8:31 AM
  • Thu, Jul. 21, 9:15 AM
    | Thu, Jul. 21, 9:15 AM | 1 Comment
  • Fri, Jun. 10, 6:36 AM
    • OncoSec Medical (ONCS) FQ3 results: Revenues: $0; R&D Expense: $3.4M (-12.8%); SG&A: $2.9M (+38.1%); Net Loss: ($6.3M) (-5.0%); Loss Per Share: ($0.37) (+22.9%); Quick Assets: $24M (-25.0%); CF Ops: ($13.7M) (-10.5%).
    • No guidance given.
    | Fri, Jun. 10, 6:36 AM
  • Thu, Jun. 9, 4:02 PM
    • OncoSec Medical (NASDAQ:ONCS): FQ3 EPS of -$0.37 beats by $0.06.
    • Cash and cash equivalents of $24.01M.
    | Thu, Jun. 9, 4:02 PM | 1 Comment
  • Fri, May 20, 12:48 PM
    | Fri, May 20, 12:48 PM | 2 Comments
  • Wed, Apr. 20, 9:15 AM
    | Wed, Apr. 20, 9:15 AM | 8 Comments
  • Wed, Apr. 20, 9:15 AM
    • Thinly traded nano cap OncoSec Medical (NASDAQ:ONCS) is up 22% premarket on increased volume in response to its announcement of encouraging follow-up data in that show treatment with ImmunoPulse interleukin-12 (IL-12) appears to enhance melanoma patients' responses to PD-1/PD-L1 therapy. The results were presented at the American Association of Cancer Research Annual Meeting in New Orleans, LA.
    • The data were generated from a single-site retrospective analysis of the company's Phase 2 study of ImmunoPulse IL-12 as monotherapy in patients with advanced melanoma. After 34 patients completing treatment with ImmunoPulse IL-12, a subset (n=14) received anti-PD-1/PD-L1 therapy, either as the next line or later line of treatment. The overall response rate (ORR) was 64% (n=9/14), including five complete responders (36%), four partial responders (29%). Two had stable disease (14%) and three progressed. In addition, eight of the 14 evaluable patients received anti-PD-1/PD-L1 treatment with no intervening therapy after treatment with ImmunPulse IL-12. The ORR in this subgroup was 75% (n=6), including four complete responders and two partial responders.
    • According to the company, analyses of multiple biomarkers appear to show treatment with ImmunoPulse IL-12 enhances the response to anti-PD-1/PD-L1 therapy by triggering the PD-1 immune checkpoint, thereby providing the "substrate" for the therapy to work.
    • ImmunoPulse IL-12 delivers a pulsed electric field to cells via a hand-held applicator which temporarily increases the porosity of the cell membranes (electroporation). DNA IL-12 is then delivered to the electroporated cells which triggers each cell to produce and secrete IL-12 protein which then identifies and eliminates cancer cells as part of a natural immune response.
    • Read now OncoSec Medical: A Look Back And A Look Forward 
    | Wed, Apr. 20, 9:15 AM | 71 Comments
  • Tue, Mar. 22, 12:41 PM
    | Tue, Mar. 22, 12:41 PM | 2 Comments
  • Tue, Mar. 8, 9:09 AM
    • OncoSec Medical (NASDAQ:ONCS): FQ2 EPS of -$0.42 beats by $0.04.
    | Tue, Mar. 8, 9:09 AM | 6 Comments
  • Wed, Mar. 2, 8:02 AM
    • Nano cap OncoSec Medical (NASDAQ:ONCS) hits its enrollment target of 21 subjects in its Phase 2 extension study of ImmunoPulse IL-12 for the treatment of advanced melanoma. The objective of the study, an extension of the OMS-I100 Phase 2 trial, is to advance the scientific understanding of ImmunoPulse by assessing an alternate dosing frequency (six-week treatment cycle) and additional biomarkers.
    • Results from both the main and extension studies should be available by Q3.
    • OncoSec's approach employs its OncoSec Medical System to deliver a pulsed electric field to cells via a hand-held applicator which temporarily increases the porosity of the cell membranes (electroporation). DNA IL-12 is then delivered to the electroporated cells which triggers each cell to produce and secrete IL-12 protein which then identifies and eliminates cancer cells as part of a natural immune response.
    | Wed, Mar. 2, 8:02 AM | 4 Comments
  • Dec. 29, 2015, 4:33 PM
    • In a regulatory filing, OncoSec Medical (NASDAQ:ONCS) discloses that Chief Medical Officer Mai Hope Le, M.D., will resign effective December 31. She will remain a consultant to assist with the transition of her duties to a successor, the search for whom is underway.
    | Dec. 29, 2015, 4:33 PM | 15 Comments
  • Dec. 8, 2015, 6:25 AM
    • OncoSec Medical (ONCS -2%) FQ1 results: Revenues: $0; R&D Expense: $3.7M (+48.0%); SG&A: $3.4M (+112.5%); Net Loss: ($7M) (-70.7%); Loss Per Share: ($0.47) (-42.4%); Quick Assets: $26.9M (-15.9%); CF Ops: ($4.7M) (-38.2%).
    • No guidance given.
    | Dec. 8, 2015, 6:25 AM
  • Dec. 8, 2015, 6:06 AM
    • OncoSec Medical (NASDAQ:ONCS): FQ1 EPS of -$0.47 beats by $0.01.
    | Dec. 8, 2015, 6:06 AM | 1 Comment
  • Nov. 4, 2015, 7:29 AM
    • OncoSec Medical (NASDAQ:ONCS) agrees to sell 2,142,860 shares of common stock at $3.50 per share to institutional investors in a registered direct offering. Buyers will also receive warrants to purchase up to an aggregate of 1,071,430 shares of common at $4.50 for a term of 5 1/2 years (exercisable after six months).
    • Net proceeds of ~$6.9M will be used for general corporate purposes.
    • Yesterday's close was $4.29.
    | Nov. 4, 2015, 7:29 AM | 43 Comments